Cervical cancer: Biomarkers for diagnosis and treatment

Clinica Chimica Acta

Volumn 445, Issue , 2015, Pages 7-11

  Dasari, Subramanyam ^a   Wudayagiri, Rajendra ^b   Valluru, Lokanatha ^a  

^a DRAVIDIAN UNIVERSITY   (India)

^b SRI VENKATESWARA UNIVERSITY   (India)

Author keywords

Biomarkers; Cancer antigen; Cervical cancer; Diagnosis; Magnetic resonance imaging; Prognosis

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CIRCULATING DNA; CYCLOOXYGENASE 2; CYTOKERATIN; DNA; GELATINASE A; GELATINASE B; GLYCOPROTEIN GP 39; HERMES ANTIGEN; HUMAN PAPILLOMA VIRUS DNA; IMMUNOSUPPRESSIVE ACID PROTEIN; MATRIX METALLOPROTEINASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS DNA; ADIPOCYTOKINE; ANTIGEN CYFRA21.1; CA 125 ANTIGEN; CD44 PROTEIN, HUMAN; CHI3L1 PROTEIN, HUMAN; CYTOKERATIN 19; LECTIN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; GENOMICS; HUMAN; NONHUMAN; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; UTERINE CERVIX CANCER; WART VIRUS; CHEMISTRY; FEMALE; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; PAPILLOMAVIRIDAE; PATHOLOGY; TUMOR RECURRENCE; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX;

ADIPOKINES; ANTIGENS, CD44; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CERVIX UTERI; DNA, VIRAL; FEMALE; HUMANS; KERATIN-19; LECTINS; MATRIX METALLOPROTEINASE 9; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRIDAE; SERPINS; UTERINE CERVICAL NEOPLASMS;

EID: 84924975916     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.03.005     Document Type: Review

References (50)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
2. Franco E.L. Cancer causes revisited: human papillomavirus and cervical neoplasia. J Natl Cancer Inst 1995, 87:779-780.
3. Brayand F., Moller B. Predicting the future burden of cancer. Nat Rev Cancer 2006, 6:63-74.
4. Senapathy J.G., Umadevi P., Kannika P.S. The present scenario of cervical cancer control and HPV epidemiology in India: an outline. Asian Pac J Cancer Prev 2011, 12:1107-1115.
5. Anant N.B., Rohit M., Abdullah F., Amit V., Dwarakanath B.S. Cancer biomarkers - current perspectives. Indian J Med Res 2010, 132:129-149.
6. Fong Y., Fortner J., Sun R.L., Brennan M.F., Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318.
7. Mao C., Hughes J.P., Kiviat N., et al. Clinical findings among young women with genital human papillomavirus infection. Am J Obstet Gynecol 2003, 188:677-684.
8. Dewar M.A., Hall K., Perchalski J. Cervical cancer screening. Past success and future challenge. Prim Care 1992, 19:589-606.
9. Gheit T., Vaccarella S., Schmitt M., et al. Prevalence of human papillomavirus types in cervical and oral cancers in central India. Vaccine 2009, 27:636-639.
10. Bast R.C., Lilja H., Urban N., et al. Translational crossroads for biomarkers. Clin Cancer Res 2005, 11:6103-6108.
11. Upender M., Rashmi-Gopal S., Sudhir S. Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discov Today 2005, 10:965-972.
12. Wang E., Panelli M.C., Marincola F.M. Genomic analysis of cancer. Princ Pract Oncol 2003, 17:1-16.
13. Wagner P.D., Verma M., Srivastava S. Challenges for biomarkers in cancer detection. Ann N Y Acad Sci 2004, 1022:9-16.
14. Malati T. Tumor markers: an overview. Indian J Clin Biochem 2007, 22:17-31.
15. INK4a-stained cervical squamous cells in liquid-based cytology samples. Cancer 2005, 105:461-467.
16. Syrjanen K.J. Immunohistochemistry in assessment of molecular pathogenesis of cervical carcinogenesis. Eur J Gynaecol Oncol 2005, 26:118-124.
17. Kjaer S.K., van den Brule A.J., Paull G., et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Br Med J 2003, 325:572.
18. Walker J.L., Wang S.S., Schiffman M.H., Solomon D. For the ASCUS LSIL Triage Study (ALTS) Group: predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS). Am J Obstet Gynecol 2006, 195:341-348.
19. Castle P.E., Solomon D., Schiffman M., Wheeler C.M. Human papillomavirus type 16 infections and 2-year absolute risk of cervical pre-cancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005, 97:1066-1071.
20. Widschwendter A., Blassnig A., Wiedemair A., Müller-Holzner E., Müller H.M., Marth C. Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett 2003, 202(2):231-239.
21. Campitelli M., Jeannot E., Peter M., et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS One 2012, 7(8):e43393.
22. Dasari S., Shouri R.N.D., Rajendra W., Valluru L. Effect of concurrent radiochemotherapy and chemotherapy on serum proteins for prospective predictors of patients with HPV induced cervical cancer. Biomed Pharmacother 2014, 68:315-320.
23. Kato H., Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977, 40:1621-1628.
24. Di Saia P.J., Creasman W.T. Clinical Gynecologic Oncology 2002, 53-112. Mosby, St. Louis, MO, USA. 6th ed.
25. Ohara K., Tanaka Y., Tsunoda H., Nishida M., Sugahara S., Itai Y. Assessment of cervical cancer radioresponse by serum squamous cell carcinoma antigen and magnetic resonance imaging. Obstet Gynecol 2002, 100:781-787.
26. Takeda M., Sakuragi N., Okamoto K., et al. Preoperative serum SCC, CA125 and CA19-9 levels and lymph node status in squamous cell carcinoma of the uterine cervix. Acta Obstet Gynecol Scand 2002, 81:451-457.
27. Gaarenstroom K.N., Kenter G.G., Bonfrer J.M.G., et al. Can initial serum CYFRA 21-1, SCC antigen and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?. Gynecol Oncol 2000, 77:164-170.
28. Chou C.Y., Wang S.T., Kuo H.C., Tzeng C.C., Yao B.L. Serum level of squamous cell carcinoma antigen and tumor size is useful to identify preoperatively patients at high risk of cervical cancer. Cancer 1994, 74:2497-2501.
29. Bolli J.A., Doering D.L., Bosscher J.R., et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994, 55:169-173.
30. Pujol J.L., Grenier J., Daures J.P., Daver A., Pujol H., Michel F.B. Serum fragments of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993, 53:61-66.
31. Bonfrer J.M.G., Gaarenstroom K.N., Kenter G.G., et al. Prognostic significance of serum fragments of cytokeratin 19 measured by CYFRA 21-1 in cervical cancer. Gynecol Oncol 1994, 55:371-375.
32. Suzuki Y., Nakano T., Ohno T., Abe A., Morita S., Tsujii H. Serum CYFRA 21-1 in cervical cancer patients treated with radiation therapy. J Cancer Res Clin Oncol 2000, 126:332-336.
33. Molina R., Filella X., Augé J.M., et al. CYFRA 21.1 in patients with cervical cancer: comparison with SCC and CEA. Anticancer Res 2005, 25:1765-1771.
34. Gold P., Freedman S.O. Specific carcinoembriyonic antigens of human digestive system. J Exp Med 1965, 122:467-481.
35. Sugarbaker P.H. Role of carcinoembriyonic antigen assay in the management of cancer. Adv Immun Cancer Ther 1985, 1:167-193.
36. Lo Gerfo P., Krupey J., Hansen H.J. Demonstration of an antigen common to several varieties of neoplasia. N Eng J Med 1971, 285:138-141.
37. Disaia P., Morrow C., Haverback B., Dyce B. Carcino-enbryonic antigen in cancer of the female reproductive system. Cancer 1977, 39:2365-2370.
38. Borras G., Molina R., Xercavins J., Ballesta A., Iglesias J. Tumor antigens CA 19.9, CA 125 and CEA in carcinoma of the uterine cervix. Gynecol Oncol 1995, 57:205-211.
39. Battaglia F., Scambia G., Panici P.B., et al. Immunosuppressive acidic protein (IAP) and squamous cell carcinoma antigen (SCC) in patients with cervical cancer. Gynecol Oncol 1994, 53:176-182.
40. Gadducci A., Elena G.M., Greco C. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol 2013, 86:104-129.
41. Ryu H.S., Chang K.H., Yang H.W., Kim M.S., Kwon H.C., Oh K.S. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion. Gynecol Oncol 2000, 76:320-325.
42. Jung Y.W., Kim S.W., Kim S., et al. Prevalence and clinical relevance of cyclooxygenase-1 and -2 expressions in stage IIB cervical adenocarcinoma. Eur J Obstet Gynecol Reprod Biol 2010, 148:62-66.
43. Uhl-Steidl M., Muller-Holzner E., Zeimet A.G., et al. Prognostic value of CD44 splices variant expression in ovarian cancer. Oncology 1995, 52:400-406.
44. Zeimet A.G., Widschwendter M., Uhl-Steidl M., et al. High serum level of soluble CD44 variant isoform v5 are associated with favorable clinical outcome in ovarian cancer. Br J Cancer 1997, 76:1646-1651.
45. Kainz C., Sliutz G., Mustafa G., et al. Cytokeratin subunit 19 measured by CYFRA 21-1 assay in follow-up of cervical cancer. Gynecol Oncol 1995, 56:402-425.
46. Subramanyam D., Rajendra W., Lokanatha V. Evaluation of soluble CD44 protein marker to distinguish the benign and squamous cell carcinoma cases in cervical cancer Patients. Med Oncol 2014, 31:1-7.
47. Lein M., Laube C., Hubner T., et al. Matrix-metalloproteinases and their inhibitors in plasma and tissue of patients with renal cell carcinoma. Int J Cancer 2000, 85:801-804.
48. Li Y., Wu T., Zhang B., Yao Y., Yin G. Matrix metalloproteinase-9 is a prognostic marker for patients with cervical cancer. Med Oncol 2012, 29(5):3394-3399.
49. Mitsuhashi A., Matsui H., Usui H., et al. Serum YKL-40 as a marker for cervical adenocarcinoma. Ann Oncol 2009, 20:71-77.
50. Konno R., Takano T., Sato S., Yajima A. Serum soluble Fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000, 6:3576-3580.